Key Takeaways
- Fire aftershock hits margins hard: EBITDA margin collapsed to 4.6% as the Hyderabad unit’s overheads, raw material transport and custom duty costs flowed through other plants; management calls this transient.
- Production, not demand, is the bottleneck: MCC revenue share fell from 83% to 70% purely because supply is constrained; pricing is rising and demand remains strong.
- Dahej expansion doubles lost capacity: A 12,000 metric tons per annum MCC facility is being built at Dahej SEZ, nearly double the 6,000-ton Hyderabad unit, with commissioning targeted for Q3 FY27.
- Cystic Fibrosis API opens a material revenue stream: R&D is complete and management sees a path to INR250 crores in revenue roughly 12 months after commercialization.
- What to watch next quarter: Whether the ad hoc insurance payment arrives before March 31, the pace of production normalization into Q4, and any decision on Hyderabad’s future use now that the land can be converted to residential or commercial.
The Hyderabad Fire: Damage, Costs & Recovery
- Overhead spillover: All Hyderabad unit overheads were spread across Dahej and Jhagadia units after the fire, directly compressing margins at the operating plants.
- Logistics penalty: Raw material from Hyderabad was physically moved to Dahej and Jhagadia, inflating landing costs with extra freight.
- Custom duty leakage: Goods were moved by paying custom duty rather than against advance licensing because the Hyderabad facility was not operational, a cost management insists will not recur once the facility question is settled.
- Gross margin erosion: Raw material cost increases shaved a further 6%–7% off gross margins in the quarter.
- Internal audit drag: Safety redefinitions, internal audits and external safety audits across existing units are slowing production during a transition period; production is expected to pick up in Q4 and thereafter.
- Hyderabad’s future is open: The plant sits on only two acres and the government has notified the land can convert to residential or commercial use; management is not moving any material to Hyderabad until there is clarity, and no reopening decision has been taken.
O.S. Reddy: "Yes, exactly this is consequent to the fire accident that carrying in third quarter also because all Hyderabad unit overheads were spread across the other units. That is one thing. And also the material transportation cost from Hyderabad unit, there is a lot of raw material was available and this has been moved to the Dahej and Jhagadia units."
Demand & Pricing: Constrained, Not Broken
- MCC demand intact: Management was explicit that the MCC revenue share drop from 83% to 70% reflects production constraints only, not any softening in demand or pricing.
- Pricing holds firm: Average realization prices for MCC, CCS and API have seen a small increase with no negative impact.
- CCS is evolving beyond trading: Customers ask for CCS alongside MCC; the company currently buys n-1 stage pre-CCS, performs one process at its facility and exports, but is now setting up its own CCS manufacturing facility because customer pull is strong.
O.S. Reddy: "Not at all. Pricing also it is increasing and then demand is there and only this is because of the production constraints."
Dahej Expansion: The Capacity Bridge
- Scale of the build: The Dahej SEZ expansion adds 12,000 metric tons per annum of MCC capacity, nearly double the 6,000-ton Hyderabad unit that went offline.
- CCS facility in parallel: A 1,800-ton CCS disintegrant facility at Dahej SEZ is targeted for commissioning in the same Q3 FY27 window.
- Management’s priority: The focus is on how fast capex cycles turn around and commissioning the whole plant, not on reviving Hyderabad, which carries legal angles.
- Capex funding undecided: Whether the Dahej and CCS facilities will be funded via equity or debt has not been decided; the board will take a call and an announcement will come at the appropriate time.
Amit Raj Sinha: "Hyderabad facility was housing a 6,000 metric tons per annum facility of MCC. Current expansion at Dahej SEZ is building up a 12,000 metric tons per annum facility. So that's nearly double the capacity. So I would say that at this moment our focus is not really to ramp up the Hyderabad facility because there are legal angles to it."
Cystic Fibrosis API: A New Growth Vector
- R&D complete, commercialization next: Product development has taken place in the R&D facility; post-development, management sees a path to INR250 crores in revenue after roughly 12 months.
- Partner search underway: The company is confident of securing a formulator or commercial partner to take the product to market.
- Competitive landscape unclear: When asked about other players in the Cystic Fibrosis API therapy segment, management said it is not known exactly and that no announcements from others have been seen so far.
- Revenue quantification deferred: Management declined to estimate how much revenue the API could contribute in the first half following commencement, calling it difficult to quantify which CEP will amplify and to what magnitude.
O.S. Reddy: "Yes, that is after 12 months. Yes, after 12 months there is because that is in R&D that product has been — that is development took place and then that is post development then there is a possibility to get this revenue INR250 crores after 12 months."
Insurance & Regulatory Milestones
- Claim submission imminent: A few documents remain pending, including from the inspector of factories and fire brigade; these are being submitted the following week.
- Ad hoc payment expected by March 31: Management expects to receive some ad hoc amount before the fiscal year closes, with the final claim likely arriving post March 31.
- Metformin CEP secured: The Metformin CEP approval came through roughly two quarters ago, adding to the API dossier.
- Six CEP filings in progress: The API R&D facility initially planned six CEP filings; some have received queries and the team is working on building up data and content, with exchange intimations promised as and when approvals come.
O.S. Reddy: "Next week we are submitting those documents and before 31st March we are expecting some ad hoc amount and post 31st March the final claim may be received."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej MCC capacity commissioning | 12,000 metric tons per annum facility | Q3 FY27 |
| Dahej CCS facility commissioning | 1,800 tons disintegrant facility | Q3 FY27 |
| Production normalization | Production picks up from Q4, gradually improving | Q4 FY26 into Q1/Q2 FY27 |
| FY27–28 guidance maintained | FY27 and FY28 as earlier; transition-period slowdown in existing units but full-year capacities come in during FY27 | FY27 partial, FY28 full normalcy |
| Margin recovery | Double-digit EBITDA expected; FY28 onwards would be good, FY27 partially a momentum | FY27 partial, FY28 full |
| Cystic Fibrosis API revenue | INR250 crores possible after 12 months post-commercialization | ~12 months from commercialization |
| Insurance ad hoc payment | Some ad hoc amount expected | Before March 31, 2026 |
| Promoter shareholding increase | Promoters intend to increase shareholding | In a few quarters, not this quarter |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Total operating income | ₹117.2 cr |
| EBITDA | ₹5.7 cr, margin of 4.6% |
| Net loss | ₹0.02 cr, PAT margin of (0.01%) |
| MCC segment revenue | ₹61.72 cr |
| O&M segment revenue | ₹13.35 cr |
| API segment revenue | ₹14.13 cr |
| Gross margin change | Reduced by 6–7% YoY, driven by raw material cost increase |
| MCC segment gross margin | ~40% |
| O&M segment gross margin | ~22% |
| API segment gross margin | ~10% |
| Cellulose-based excipient capacity | 18,000 MTPA (Dahej 9,882 MTPA, Jhagadia 8,118 MTPA) |
| Capacity utilization | 70% to 73% |
| Exports share of production | ~62% |
| MCC volumes (9M FY26) | ~10,000 MT against 9M capacity of ~13,500 MT |
| Promoter pledge | ₹3.77 cr shares, less than 10% of total share capital, ~26% of promoter holding |
| Insurance claim expected | ~₹70 cr total (fixed assets ₹48 cr, inventory ₹4 cr, BI loss ₹25 cr); ad hoc ₹20–25 cr expected |
| Cystic Fibrosis API revenue guidance | ₹250 cr, expected after 12 months from commercialization |
| Long-term debt | Nil, only working capital debt outstanding |